Q2 EPS Forecast for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research boosted their Q2 2025 EPS estimates for Corcept Therapeutics in a report released on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their previous estimate of $0.34. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). The company had revenue of $181.89 million during the quarter, compared to analysts’ expectations of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Other research analysts have also recently issued reports about the stock. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $115.00 target price on shares of Corcept Therapeutics in a research note on Thursday, February 27th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.75.

Corcept Therapeutics Stock Up 1.9 %

CORT opened at $58.66 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.19 billion, a price-to-earnings ratio of 46.56 and a beta of 0.61. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00. The company’s 50-day moving average price is $61.49 and its two-hundred day moving average price is $53.81.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Corcept Therapeutics by 50.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,724 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 2,578 shares during the last quarter. Cache Advisors LLC bought a new stake in Corcept Therapeutics in the 4th quarter worth $378,000. Public Employees Retirement System of Ohio grew its holdings in Corcept Therapeutics by 269.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 2,086 shares during the last quarter. Vise Technologies Inc. bought a new stake in Corcept Therapeutics in the 4th quarter worth $204,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Corcept Therapeutics by 11.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,713 shares of the biotechnology company’s stock worth $11,323,000 after acquiring an additional 22,361 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Insider Activity

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sean Maduck sold 20,000 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,627 shares of company stock valued at $2,557,674 over the last quarter. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.